Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UCART20x22 · 1 trial · 1 indication
Incidence, nature and severity of adverse events and serious adverse events in relation to UCART20x22 and/or lymphodepletion
| Arm | Type | Description |
|---|---|---|
| Dose finding part | EXPERIMENTAL | UCART20x22 tested at several dose levels until the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) is identified. Dose expansion part: UCART20x22 administered at the RP2D determined during the dose finding part |
| Name | Type | Description |
|---|---|---|
| UCART20x22 | BIOLOGICAL | Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen |
| CLLS52 | BIOLOGICAL | A monoclonal antibody that recognizes a CD52 antigen |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Relapsed or refractory (R/R) mature B-NHL per 2016 WHO criteria and positive for CD20 and/or CD22 * Subjects with NHL subtypes defined by WHO: * Dose-Finding Part: R/R mature B-NHL (except chronic lymphoc...
UCART20x22 is an investigational cell therapy being studied for the treatment of B-cell non-Hodgkin lymphoma (B-NHL). It is in Phase 1 clinical development and is not yet approved for any indication. The trial enrolls adults aged 18 years and older with this condition.
UCART20x22 targets CD20 and CD22, two antigens expressed on the surface of B cells. By engaging both antigens, the therapy is designed to recognize malignant B cells in B-cell non-Hodgkin lymphoma. Both CD20 and CD22 belong to the antigen target class.
UCART20x22 is being developed by Cellectis S.A., a biopharmaceutical company listed under the ticker CLLS. Cellectis is the sponsor of the clinical program evaluating the therapy in B-cell non-Hodgkin lymphoma.
UCART20x22 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or any other regulatory agency. The Phase 1 study is currently recruiting participants and has an planned enrollment of 80 patients.
UCART20x22 is being evaluated in one clinical trial, NCT05607420, titled Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma. The Phase 1 trial is currently recruiting and plans to enroll 80 participants across the United States, France, and Spain. It is an uncontrolled, open-label study.